Theragenics

Theragenics Corporation is a leader in the production and sales of implantable radiation devices ("seeds") used in thetreatment of cancer. The Company produces and sells TheraSeed(R), which is a U.S. Food and Drug Administration (FDA) licensed device, based on the radioactive isotope palladium 103 (Pd-103). The Company received FDA clearance

to market TheraSeed(R) in 1986 and commenced commercial production and product sales in 1987. Currently, TheraSeed(R) is used primarily in the treatment of early stage prostate cancer. In the treatment, TheraSeeds(R) are implanted ("seeding") into the prostate in a one-time, minimally invasive procedure. The radiation emitted by the seeds is contained within the immediate prostate area, killing the cancerous tumor while sparing surrounding healthy cells and organs from any significant dose of radiation. TheraSeed(R) has been shown in independent clinical studies to offer success rates that are comparable to or better than conventional therapies for the treatment of prostate cancer, while

being associated with a reduced incidence of adverse side effects.

Contact Details: 5203 Bristol Industrial Way Buford GA 30518 United States of America Tel: 770-271-0233 Fax: 770 831 4369 Email: WWW: www.theragenics.com/

Loading...

Recent Publications by Theragenics:
Mammographic x-ray unit kilovoltage test tool based on k-edge absorption effect. A simple tool to determine the peak kilovoltage (kVp) of a mammographic...	10th April, 2003	Neely Nuclear Research Center, Georgia Institute of Technology, Atlanta	Med Phys. 2002 Sep;29(9):2169-76.

BioNews Results for Theragenics:
Theragenics Reports Revenue & Earnings for Third Quarter 2009	SmartBrief:  Nov 8 2009 11:40AM Matching: theragenics
Theragenics Reports Revenue & Earnings for Third Quarter 2009	Business Wire UK:  Nov 5 2009 3:56PM Matching: theragenics
Theragenics Reports Revenue & Earnings for Third Quarter 2009	Business Wire UK:  Nov 5 2009 3:53PM Matching: theragenics
Theragenics Reports Revenue & Earnings for Third Quarter 2009	FinanzNachrichten.de:  Nov 5 2009 12:37PM Matching: theragenics
Theragenics Reports Revenue & Earnings for Third Quarter 2009	Genetic Engineering News:  Nov 5 2009 1:38PM Matching: theragenics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Theragenics news.

Theragenics Clinical Trials:
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System

Theragenics Patents:
US Patent No.	Title
7497820	Expandable brachytherapy device
4702228	X-ray-emitting interstitial implants
4784116	Capsule for interstitial implants
5405309	X-ray emitting interstitial implants
6323501	Container for storing and shipping radioactive materials
→View more Theragenics patents.

Theragenics (TGX) Financial information Links from Barchart
TGX Quote from from Barchart.com
TGX Chart from from Barchart.com
TGX Profile from from Barchart.com
TGX Opinion from from Barchart.com
→View more Theragenics finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 586 times since April 2007, the link to the organisation's website has been followed 92 times

Recent Search Terms used to find this page: Theragenics Pharma | theraseed ocular | Theragenics emails | theragenics opinion | theraseed treatment centers | theragenics careers | theraseed radiation implant | .

Search for more companies in Buford

Search for more companies in GA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Theragenics